The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

Cancer

Volumn 118, Issue 14, 2012, Pages 3531-3537

  Garg, Ravin ^a   Wierda, William ^a   Ferrajoli, Alessandra ^a   Abruzzo, Lynne ^a   Pierce, Sherry ^a   Lerner, Susan ^a   Keating, Michael ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

13q; biallelic; chronic lymphocytic leukemia; monoallelic; prognostics

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; LENALIDOMIDE; MITOXANTRONE; PROTEIN KINASE ZAP 70; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; BIALLELIC CHROMOSOME DELETION; CANCER SURVIVAL; CHI SQUARE TEST; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DATA BASE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HOMOZYGOSITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MONOALLELIC CHROMOSOME DELETION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANK SUM TEST;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84863335070     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26593     Document Type: Article

References (29)

1. Rozman C, Montserrat E,. Chronic lymphocytic leukemia. N Engl J Med. 1995; 333: 1052-1057.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS,. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219-234.
3. Juliusson G, Merup M,. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol. 1998; 25: 19-26. (Pubitemid 28090908)
4. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323: 720-724. (Pubitemid 20288941)
5. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002; 100: 1410-1416. (Pubitemid 34864299)
6. Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P,. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999; 77: 266-281. (Pubitemid 29146578)
7. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1910-1916. (Pubitemid 32064784)
8. Liu Y, Hermanson M, Grandér D, et al. 13q Deletions in lymphoid malignancies. Blood. 1995; 86: 1911-1915.
9. Liu Y, Grandér D, Söderhäll S, Juliusson G, Gahrton G, Einhorn S,. Retinoblastoma gene deletions in B-cell lymphocytic leukemia. Genes Chromosomes Cancer. 1992; 4: 250-256.
10. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletion and down-regulation of micro-RNA genes miR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99: 15524-15529. (Pubitemid 35403967)
11. Rai K, Patel DV,. Chronic lymphocytic leukemia. In:, Hoffman R, Benz EJ, Shaffil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2000: 1350-1363.
12. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997. (Pubitemid 26189840)
13. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48: 198-206. (Pubitemid 11064396)
14. Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C,. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol. 1986; 62: 567-574.
15. Di Giovanni S, Valentini G, Carducci P, Giallonardo P,. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol. 1989; 81: 181-185. (Pubitemid 19186451)
16. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 1764-1775. (Pubitemid 36514707)
17. Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997; 89: 2516-2522. (Pubitemid 27143300)
18. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995; 85: 1580-1589.
19. Bullinger L, Krautle C, Busch R, et al. Incidence and correlation of genomic aberrations with clinical and biological risk factors in B-CLL stage Binet-A within the CLL1 trial of the GCLLSG [abstract]. Blood. 2001; 98 (suppl 1): 359a. Abstract 1512. (Pubitemid 33787608)
20. Stilgenbauer S, Ritgen M, Bullinger L, et al. Genomic aberrations in the CLL trial of the German CLL Study Group (GCLLSG): deletion 11q23 identifies patients with molecular disease persistence after autologous high dose therapy [abstract]. Blood. 2001; 98 (suppl 1):Page. Abstract 3180.
21. Juliusson G, Oscier D, Gahrton G, et al. International Working Party on Chromosomes in CLL (IWCCLL). Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 662 patients. Leuk Lymphoma. 1991; 5 (suppl 1): 21-25.
22. Reddy KS,. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridization panel. Br J Hematol. 2006; 132: 705-722. (Pubitemid 43381632)
23. Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in situ, hybridization; correlation with significant biological features on B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003; 121: 287-295. (Pubitemid 36560596)
24. Fink S, Geyer S, Shanafelt, et al. Clinical significance of homozygous D13S319 deletion in b-cell chronic lymphocytic leukemia (B-CLL) [abstract]. Blood. 2004; 2799: 766a. Abstract 104.
25. Chena C, Avalos J, Bezares R, et al. Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies. Eur J Haematol. 2008; 81: 94-99. (Pubitemid 352019631)
26. Pfeifer D, Pantic M, Skatulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood. 2007; 109: 1201-1210.
27. Ripollés L, Ortega M, Ortuño F, et al. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2006; 171: 57-64. (Pubitemid 44635753)
28. Van Dyke DL, Shanafelt TD, Call TG, et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol. 2009; 148: 544-550.
29. Hernández JA, Rodríguez AE, González M, et al. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica. 2009; 94: 364-371.